ENSC
Ensysce Biosciences, Inc.
ENSC's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over ENSC overall, supported by stronger fundamentals and stronger valuation.
ENSC Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
ENSC's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ENSC PE Valuation
ENSC has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ENSC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect ENSC's losses to shrink, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ENSC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$5.75 | +$8.47 |
| Q2 2026 | -$2.52 | +$9.36 |
| Q1 2026 | -$3.11 | +$11.28 |
| Q4 2025 | -$3.98 | +$17.27 |
| Q3 2025 | -$14.22 | +$7.68 |
| Q2 2025 | -$11.88 | +$24.12 |
| Q1 2025 | -$14.39 | +$33.01 |
| Q4 2024 | -$21.25 | +$49.10 |
ENSC lost $5.75 per share over the past year, a smaller loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ENSC on earnings quality, reporting a profit while its opponent remains loss making.
ENSC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | +342% |
| Q2 2026 | $1.2M | -15% |
| Q1 2026 | $961K | -27% |
| Q4 2025 | $1.9M | +44% |
| Q3 2025 | $493.1K | -86% |
| Q2 2025 | $1.4M | +654% |
| Q1 2025 | $1.3M | +332% |
| Q4 2024 | $1.3M | +153% |
ENSC's revenue is recovering but still below its 2024 peak: $2M last quarter, up 342% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3781% | -3023 points |
| Q2 2026 | -221% | -94 points |
| Q1 2026 | -371% | -222 points |
| Q4 2025 | -148% | +127 points |
| Q3 2025 | -759% | -778 points |
| Q2 2025 | -128% | +948 points |
| Q1 2025 | -149% | +454 points |
| Q4 2024 | -274% | +338 points |
ENSC's operating margin was −3781% last quarter, down 3023 points from the same quarter a year ago, near the bottom of its range since 2021.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ENSC on profitability, with a higher operating margin.
ENSC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$744.4K |
| Q1 2026 | -$3.5M | -$1.8M |
| Q4 2025 | -$1.5M | -$761.7K |
| Q2 2025 | -$2.7M | -$397K |
| Q1 2025 | -$1.7M | +$1.7M |
| Q4 2024 | -$764.1K | +$1M |
| Q3 2024 | -$1M | +$1.2M |
| Q2 2024 | -$2.3M | +$798.7K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with ENSC at up 6.3%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ENSC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +40% | +5.2M shares |
| 1 year | +530% | +15.3M shares |
| 3 years | +25787% | +18.1M shares |
| 5 years | +985979% | +18.2M shares |
| Available history | +1077056% | +18.2M shares |
ENSC has 18M diluted shares, up 530% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2020 | $136.3M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ENSC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ENSC Net Leverage
ENSC's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ENSC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 20.9 | Neutral |
ENSC's weekly RSI is 45 (neutral) and its Stochastic is 21 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ENSC PE vs Healthcare Sector
| Metric | ENSC | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ENSC has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ENSC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.43 | 9.3% below |
| 20 week MA | $0.40 | 2.5% below |
| 50 week MA | $0.53 | 26% below |
| 100 week MA | $1.97 | 80% below |
| 200 week MA | $14.8 | 97% below |
ENSC is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ENSC on trend strength, trading above more of its moving averages.
ENSC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $37,224.0 | $47,808.0 | +28% |
| 2021 | $47,808.0 | $18,432.0 | -61% |
| 2022 | $18,432.0 | $129.6 | -99% |
| 2023 | $129.6 | $15.9 | -88% |
| 2024 | $15.9 | $8.88 | -44% |
| 2025 | $8.88 | $1.10 | -88% |
| 2026 YTD | $1.10 | $0.39 | -65% |
ENSC has finished five years in a row lower, and it's down 65% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ENSC on returns for 2026, with the stronger performance.